Elanco Animal Health stock | Price, analyst rating, price target & growth

Elanco Animal Health

NYSE:ELAN

$ 21,30

$-0,39 (-1,80%)

21,30 $

$-0,39 (-1,80%)

End-of-day quote: 12/10/2025

Elanco Animal Health Stock Value

Analysts currently give NYSE:ELAN a rating of Outperform.

Outperform

Elanco Animal Health Company Info

EPS Growth 5Y

-3,01%

Market Cap

$10,58 B

Long-Term Debt

$4,28 B

Short Interest

3,94%

Annual earnings

02/24/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

1954

Industry

Health Care

Country

United States

ISIN Number

US28414H1032

Website

http://www.elanco.com

Analyst Price Target

$25,00

17.37%

Last Update: 12/11/2025

Analysts: 12

Highest Price Target $30,00

Average Price Target $25,00

Lowest Price Target $18,00

In the last five quarters, Elanco Animal Health’s Price Target has risen from $14,86 to $19,11 - a 28,60% increase. Twelve analysts predict that Elanco Animal Health’s share price will increase in the coming year, reaching $25,00. This would represent an increase of 17,37%.

Top growth stocks in the health care sector (5Y.)

What does Elanco Animal Health do?

Elanco Animal Health Incorporated and its subsidiaries (Elanco) operate as a global animal health company. The company is dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The company partners with farmers, pet owners, veterinarians, and society to create value and help its customers improve the health of animals in their care, while also making a meaningful impact on the communities the company serves. The company's diverse, du...

Elanco Animal Health Incorporated and its subsidiaries (Elanco) operate as a global animal health company.

The company is dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets.

The company partners with farmers, pet owners, veterinarians, and society to create value and help its customers improve the health of animals in their care, while also making a meaningful impact on the communities the company serves. The company's diverse, durable product portfolio is sold in more than 90 countries and serves animals across many species, primarily: dogs and cats (collectively, pet health), and cattle, poultry, swine, sheep, and prior to the divestiture of its aqua business in July 2024, aqua (collectively, farm animal).

In August 2020, the company acquired Bayer Animal Health, marking the largest acquisition in industry history. This acquisition enabled the company to become a more diverse, durable and global company with greater reach and scale. This acquisition also helped the company expand its portfolio, creating a better balance between the company’s pet health and farm animal products and between the United States (U.S.) and international markets, while also expanding its omnichannel presence in both the veterinary clinic and in retail markets, including e-commerce.

The company has continuously strengthened and expanded its three-pronged strategy: Innovation, Portfolio, and Productivity, which remains its foundation for sustained growth and profitability. The company's focused strategy prioritizes certain assets, including late-stage potential blockbusters, while maximizing life cycle management and refilling the early-stage pipeline to achieve a consistent flow of innovation. The company also continues to optimize its diverse portfolio to grow, leveraging its deep, established customer relationships and expanding product offerings.

Commercial Operations

The company operates its business as a single segment within the animal health industry, dedicated to fulfilling its intention of Food and Companionship Enriching Life. The company advances this intention by offering a comprehensive portfolio of products in the pet health and farm animal product categories.

Contract manufacturing and other represents revenue from arrangements in which the company manufactures products on behalf of a third party and royalty revenue.

International Operations

The company's operations are conducted globally. The U.S. is the company’s largest market, accounting for 46% of its total revenue in 2024. By total revenue, China, Brazil, and the United Kingdom (U.K.) are its largest markets outside the U.S.

Products

The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals.

Pet Health: The company's pet health products help pets live longer, healthier, and more active lives. Its global pet health portfolio is focused on parasiticides, vaccines, and therapeutics. The company has one of the broadest parasiticide portfolios in the pet health market based on indications, species, and formulations, with products that protect pets from fleas, ticks, and internal parasites. The Advantage Family of brands (Advantage, K-9 Advantix, Advocate, AdTab, among others) and Seresto products are over-the-counter treatments for the prevention and elimination of fleas and ticks and complement its prescription parasiticide products, which include the Credelio Family of brands (Credelio, Credelio Cat, Credelio Plus), Interceptor Plus, Drontal Family of brands (Doncit, Drontal, and Drontal Plus), and Trifexis. The company's vaccines portfolio provides differentiated prevention coverage for a number of important pet health risks and is available in the U.S. only. In therapeutics, it has a broad pain portfolio for dogs and cats across modes of action, indications, and disease stages. Pet owners are increasingly treating osteoarthritis in their pets, and its Galliprant product offers a convenient at-home solution for pet owners. Additionally, the company has products that offer treatment for otitis (ear infections) and treatments for certain cardiovascular and dermatology indications.

Farm Animal: The company's farm animal products help farmers improve animal health and wellbeing and raise livestock more sustainably, delivering more food while using fewer resources and enhancing the integrity of the food supply. Its farm animal portfolio of products for cattle (beef and dairy), swine, and poultry is primarily focused on: efficiency and performance; disease prevention and treatment; food safety; and sustainability. The company's products include medicated feed additives, injectable antibiotics, vaccines, insecticides, and enzymes, among others. Key farm animal products Rumensin, Baytril, and Experior are used extensively in cattle, while its Maxiban and Monteban products are valuable offerings for the control and prevention of intestinal disease in poultry.

In 2024, the company's top five selling products and/or product families were its Advantage Family (cats and dogs), Seresto (cats and dogs), Rumensin (cattle), Maxiban / Monteban (poultry), and its Credelio Family (cats and dogs). These products and product families combined to represent approximately 36% of the company’s total revenue in 2024, with the company’s largest product family, Advantage Family, representing approximately 10% of total revenue.

Pet Health Products

Advantage Family: Family of topical applications that provide broad-spectrum protection against and treatment of fleas, ticks, mosquitoes, lice, and biting flies. Certain products within the Advantage Family also provide protection against heartworm, lungworm, and other gastrointestinal worm infections, including roundworms, whipworms, and hookworms.

Atopica: Controls atopic dermatitis.

Credelio Family: Family of oral products that kills adult fleas, treats flea infestations, and treats and controls tick infestations. The introduction of Credelio Quattro in January 2025 adds a monthly chewable tablet for dogs that protects against fleas, ticks, heartworms, roundworms, hookworms, and three different species of tapeworms.

Drontal Family: Family of injectable and oral tablet dewormers indicated for the removal of tapeworms, hookworms, roundworms, and whipworms.

Galliprant: Controls pain and inflammation associated with osteoarthritis.

Interceptor Plus: Prevents heartworm disease and helps treat and control roundworm, hookworm, whipworm, and tapeworm infections.

Milbemax: Treats and controls parasitic infections due to common intestinal worms.

Onsior: Controls postoperative pain and inflammation associated with certain surgeries.

Seresto: Flea and tick collar with a patented low dose, slow-release technology that kills and repels fleas and ticks, which may transmit vector-borne diseases and kills lice for up to 8 months.

Trifexis: Prevents heartworm disease, kills fleas, helps prevent flea infestations, and also helps treat and control hookworms, roundworms, and whipworms.

TruCan (vaccines): Includes multiple products that collectively protect against distemper, adenovirus, parvovirus, corona, parainfluenza, leptospira canicola, and other diseases.

Farm Animal Products

AviPro (vaccines): Includes multiple products that collectively protect against Newcastle disease, infectious bronchitis, fowl cholera, paramyxovirus Type 3, Bursal Disease, other diseases, and foodborne pathogens like Salmonella.

Baytril: Injectable antibiotic active against bacterial respiratory disease pathogens. Baytril is a shared-class antibiotic.

Catosal: Injectable for prevention or treatment of deficiencies of vitamin B12 and phosphorus.

Denagard: Treats swine dysentery. Denagard is a shared-class antibiotic.

Experior: Reduces ammonia gas emissions from an animal or its waste.

Hemicell: Enzyme supplement for poultry and swine feeds.

Maxiban / Monteban: Prevents coccidiosis in broiler chickens. Maxiban and Monteban are animal-only antibiotics and ionophores.

Pulmotil: Controls swine respiratory disease and bovine respiratory disease (BRD). Pulmotil is a shared-class antibiotic.

Rumensin: Improves feed and milk production efficiency and increases the rate of weight gain in cows. Also prevents and controls coccidiosis for cows, calves (excluding veal calves), and goats. Rumensin is an animal-only antibiotic and an ionophore.

Surmax: Prevents necrotic enteritis in broiler chickens. Surmax is an animal-only antibiotic.

A key element of the company's targeted value creation strategy is to drive revenue growth through portfolio development and product innovation. The company continues to pursue the development of new chemical and biological molecules, as well as additional registrations and indications for current products. Its future growth depends on both its pipeline of new products, including new products it develops internally, develops with partners, or that it is able to obtain through licenses or acquisitions, and the life cycle management of its existing products.

New product development and regulatory highlights during 2024 included the following:

Bovaer: In May 2024, the U.S. Food and Drug Administration (FDA) completed its comprehensive, multi-year review of Bovaer (3-NOP), a first-in-class methane-reducing feed ingredient for use in lactating dairy cattle. Producers began feeding the product to cattle in the U.S. during the third quarter of 2024.

Zenrelia: The company received final FDA approval for Zenrelia, a JAK inhibitor targeting control of pruritus and atopic dermatitis in dogs, in September 2024. It launched Zenrelia shortly after final approval, with the first sales occurring in late September. The company has also received approval for Zenrelia in Brazil, Canada, and Japan. Additional reviews are ongoing in other key markets, including Europe, the U.K., and Australia.

Credelio Quattro: In October 2024, the company received final approval from the FDA for Credelio Quattro, a monthly chewable tablet for dogs that protects against fleas, ticks, heartworms, roundworms, hookworms, and three different species of tapeworms. Credelio Quattro was launched, with the first commercial sale occurring in January 2025.

Experior: In October 2024, the company received multiple combination clearance approvals from the FDA for Experior to be used in combination with other farm animal products, allowing for broader use in heifers, which represent nearly 40% of the fed cattle population in the U.S.

Seasonality

While many of the company's products are sold consistently throughout the year, it does experience seasonality in its pet health business due to increased demand for certain parasiticide product offerings in the first half of the year (year ended December 31, 2024). For example, in 2024 approximately 70% and 55% of total annual revenue generated by its higher-margin parasiticide products Seresto and Advantage Family, respectively, occurred during the first half of the year, which is reflective of the flea and tick season in the Northern Hemisphere.

Sales and Marketing

Through the company’s global sales force of over 2,200 sales representatives, its veterinary consultants, and its key distributors, the company seeks to build strong customer relationships and fulfill demand for its products. Its sales representatives visit its customers, including consultants, veterinarians, farm animal producers, and resellers, to inform, promote, and sell its products and to support customers. Its veterinary consultants are available to provide scientific consulting focused on disease management and herd management, training and education on diverse topics, including responsible product use, and generally have advanced degrees in veterinary medicine, veterinary nutrition, or other agriculture-related fields. These direct relationships with customers allow the company to better understand their needs and provide it access to customer decision makers. Additionally, its sales representatives and veterinary consultants focus on collaborating with its customers to educate and support them on topics, such as local disease awareness and to help them adopt new and more sophisticated animal health solutions. In addition, its sales and marketing organization provides enhanced value by supporting farm animal producers to maximize their yields and reduce their costs. Furthermore, its expertise and data analytics help its customers analyze large amounts of health and production data in order to improve production efficiency and business performance.

Customers

The company primarily sells its pet health products to third-party distributors and retailers, as well as directly to veterinarians who typically then sell its products to pet owners. It primarily sells its farm animal products to third-party distributors and directly to a diverse set of farm animal producers, including beef, dairy, pork, and poultry operations. Its omnichannel presence allows it to sell into both the veterinary clinic and retail markets, including e-commerce. Certain top-selling pet health products, including the Advantage Family and Seresto, are offered through these channels. Its largest customer, an affiliate of Cencora, Inc., is a third-party veterinary distributor and represented approximately 11% of its total revenue in 2024. Its second-largest customer, which is also a third-party distributor, represented approximately 6% of revenue in 2024.

Research and Development

The company's research and development expenses totaled $344 million in 2024.

Competition

The company's primary competitors include animal health medicines and vaccines companies, such as Zoetis Inc., Boehringer Ingelheim Vetmedica, Inc., the animal health division of Boehringer Ingelheim GmbH, and Merck Animal Health, the animal health division of Merck & Co., Inc.

Intellectual Property

The company's product portfolio and certain product candidates enjoy the protection of approximately 6,700 patents and applications, filed in over 90 countries, with a concentration in its major markets, as well as other markets with strong patent laws and protections.

Below is a summary of its recent and upcoming key patent expirations:

Galliprant is protected by patents in the U.S., Europe, Canada, Japan, and other key markets. While patents covering the active ingredient, grapiprant, expired in 2021 in all markets except Japan, patents covering the physical form of the active ingredient remain in force and will expire between 2026 and 2031, depending on jurisdiction. Patent coverage relating to methods of use and formulation will expire in 2035 in most jurisdictions.

The Seresto formulation patent will expire in the U.S. in September 2027. In Europe, the formulation patents will expire in June 2025, but in some countries, including Spain, Italy, and the U.K., supplementary protection certificates (SPCs) have been granted that expire in August 2026.

Patent coverage for Milbemax/Interceptor chewable products expired in July 2024 in Europe and other key markets. Patent coverage for Interceptor Plus extends through October 2028 in the U.S.

The U.S. patent for Experior's active ingredient, lubabegron, will expire in April 2025. Coverage for Experior methods of use will expire in 2037 in the U.S. and 2035 in other key markets.

Additionally, many of the company's vaccine products, including the TruCan family of vaccines, are based on proprietary or patented master seeds and formulations.

The company maintains more than 12,800 trademark applications and registrations in major regions, primarily identifying products dedicated to the care of livestock and pets.

History

Elanco Animal Health Incorporated was founded in 1954. The company was incorporated in Indiana in 2018.

Elanco Animal Health Questions and Answers

Which sectors generate sales and which are the top 3 markets?

Revenue distribution by sectors: Livestock: approx. 55% Pets: approx. 45% TOP 3 markets: USA: approx. 40% Europe: approx. 25% Latin America: approx. 15% Elanco Animal Health Incorporated generates the majority of its revenue from the livestock and pets sectors. The U.S. market is the largest sin...

At which locations are the company’s products manufactured?

Production sites of Elanco Animal Health: Elanco Animal Health produces its products at several locations worldwide. The most important production sites include: USA: Several plants, including in Fort Dodge, Iowa, and Clinton, Indiana. Europe: Production facilities in countries such as Germany and...

What strategy does Elanco Animal Health pursue for future growth?

Revenue Growth: Estimated at 6-8% annually (forecast for 2025 based on 2023 data) Elanco Animal Health Incorporated pursues a strategy focused on innovation, geographic expansion, and operational efficiency to secure future growth. A key element of this strategy is continuous investment in research...

Which raw materials are imported and from which countries?

Main raw materials: Active ingredients for animal health products, packaging materials, excipients Countries of origin: China, India, Germany, USA Elanco Animal Health Incorporated sources a variety of raw materials necessary for the production of their animal health products. This includes pharmace...

How strong is the company’s competitive advantage?

Market Share: Approximately 10% in the global animal health market (2024 estimate) R&D Expenses: 9% of revenue (2023) Product Portfolio: Over 200 products Elanco Animal Health Incorporated has a significant competitive advantage in the animal health market, supported by several factors. Firstl...

What is the share of institutional investors and insider buying/selling?

Institutional Investor Share: approx. 95% (2025, estimated based on historical data) Insider Buys/Sells: No significant transactions in the last year (estimated, 2025) Elanco Animal Health Incorporated has traditionally had a high proportion of institutional investors, indicating the trust of large...

What percentage market share does Elanco Animal Health have?

Market share of Elanco Animal Health: Estimated 8-10% (2025) Major competitors and their market shares: Zoetis Inc.: 25-30% Boehringer Ingelheim Animal Health: 15-20% Merck Animal Health: 10-15% Bayer Animal Health: 8-12% Elanco Animal Health: 8-10% Ceva Santé Animale: 5-7% Virbac: 3-5% Elanco Ani...

Is Elanco Animal Health stock currently a good investment?

Revenue Growth: 7.8% (2024) R&D Expenses: 9.5% of revenue (2024) Market Share in the Animal Health Sector: 12% (2024) Elanco Animal Health Incorporated recorded a revenue growth of 7.8% in 2024, attributed to strong demand for animal health products and successful integration of new products. Th...

Does Elanco Animal Health pay a dividend – and how reliable is the payout?

Dividend: No payout (2025) Elanco Animal Health Incorporated has not paid any dividends in recent years. The company has focused on investing its resources in research and development as well as strategic acquisitions to strengthen its market position. The reliability of dividend payout is therefore...

Elanco Animal Health Stock Value

Elanco Animal Health Company Info

Analyst Price Target

Top growth stocks in the health care sector (5Y.)

What does Elanco Animal Health do?

Elanco Animal Health Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal